Recently clinical studies of PARP-inhibitors have been extended across different tumor types harboring BRCA-mutations, including also “BRCA-like” sporadic tumors with homologous recombination deficiency (HRD). The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.